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Abstract
Background: Dengue illness causes 50–100 million infections worldwide and threatens 2.5 billion people in the tropical and
subtropical regions. Little is known about the disease burden and economic impact of dengue in higher resourced countries
or the cost-effectiveness of potential dengue vaccines in such settings.
Methods and Findings: We estimate the direct and indirect costs of dengue from hospitalized and ambulatory cases in
Singapore. We consider inter alia the impacts of dengue on the economy using the human-capital and the friction cost
methods. Disease burden was estimated using disability-adjusted life years (DALYs) and the cost-effectiveness of a potential
vaccine program was evaluated. The average economic impact of dengue illness in Singapore from 2000 to 2009 in
constant 2010 US$ ranged between $0.85 billion and $1.15 billion, of which control costs constitute 42%–59%. Using
empirically derived disability weights, we estimated an annual average disease burden of 9–14 DALYs per 100 000
habitants, making it comparable to diseases such as hepatitis B or syphilis. The proportion of symptomatic dengue cases
detected by the national surveillance system was estimated to be low, and to decrease with age. Under population
projections by the United Nations, the price per dose threshold for which vaccines stop being more cost-effective than the
current vector control program ranged from $50 for mass vaccination requiring 3 doses and only conferring 10 years of
immunity to $300 for vaccination requiring 2 doses and conferring lifetime immunity. The thresholds for these vaccine
programs to not be cost-effective for Singapore were $100 and $500 per dose respectively.
Conclusions: Dengue illness presents a serious economic and disease burden in Singapore. Dengue vaccines are expected
to be cost-effective if reasonably low prices are adopted and will help to reduce the economic and disease burden of
dengue in Singapore substantially.
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Introduction
Dengue and dengue hemorrhagic fever (DF and DHF,
respectively) are substantial public health threats throughout the
tropical and subtropical regions [1,2]. The distribution of dengue
and its vectors has expanded dramatically over the last 30 years,
among other reasons because of insufficient mosquito control,
increasing urbanization and air travel [3,4]. As a result, about 2.5
billion people worldwide are threatened by dengue infection, with
an estimated 50–100 million infections and 12,000 deaths, mainly
among children, annually [5,6].
Determining the disease and economic burden of dengue is
crucial in the allocation of scarce public health resources among
competing health problems, and to allow for evaluations of the
cost-effectiveness of interventions. However, few studies have
estimated the economic impact and disease burden of dengue at
the national level – while some studies have focused on resource-
limited Latin American [7,8,9,10,11,12] and Asian countries
[10,13,14,15,16,17], the broad geographic range of the Aedes
mosquito vectors also encompasses highly resourced countries
and countries that will become highly resourced over the
decades ahead. Studies of the health economics of dengue in
www.plosntds.org 1 December 2011 | Volume 5 | Issue 12 | e1426
such settings are scarce, even though the impact of dengue there
is substantial.
Singapore presents unique characteristics of dengue infection.
Vector control programs introduced in the 1970s led to a considerable
decline in vector density and DHF cases [18]; but despite the
effectiveness of the vector control programs in reducing vector indices,
dengue resurged in Singapore in the 1990s, due to a number of factors
chief of which is the reduction of the herd protection in the 1970s and
1980s [19]. As a result, in contrast to other countries in Southeast Asia
where dengue is primarily a pediatric disease, over 85% of the reported
dengue cases in Singapore are young adults, and the incidence of
dengue in the elderly is also growing [18]. Cyclical epidemics have
occurred since the 1990s, peaking in 2005 when the incidence of
reported confirmed DF was 335 per 100,000 population [20].
Several complexities bedevil the estimation of the economic
impact of dengue at the national level. One of the main difficulties
is the large proportion of cases that are not reported to national
surveillance systems [1]. It is therefore necessary to adjust national
statistics using independent cohort or serological studies [21,22].
Another complexity resides in the heterogeneity of costs: to obtain
reliable estimates, it is necessary to combine medical costs with
indirect costs borne by the individual, society (e.g. school loss,
work absenteeism), and vector control costs. In addition, due to the
cyclic nature of dengue epidemics [23,24], there is no single
representative year for dengue infection in a particular region. To
stabilize the estimates, projections need to be based on multi-year
epidemic cycles [11]. In Singapore, the availability of serological
and epidemiological studies independent of the national surveil-
lance system provides a unique opportunity to understand the
costs of dengue and allocate resources to control effectively.
At the time of writing, there are tetravalent dengue vaccine
candidates in various phases of clinical trials [25,26,27], and the
determination of cost-effectiveness of these vaccines has been
identified as an urgent research need [25]. To address these issues,
we performed an estimate of the economic impacts and disease
burden of dengue illness in Singapore from 2000 to 2009.
Methods
Data collection
Annual national age-dependent DF and DHF cases reported
from 2000 to 2009 were obtained from the national surveillance
system [28,29]. Reporting of DF and DHF laboratory diagnosed
cases to the Ministry of Health is legally mandated in Singapore.
The cases notified by registered medical practitioners and
accredited laboratories are collated and totals published weekly
by the Communicable Diseases Division of the Ministry of Health
[28]. Notification data were complemented with two dengue
studies: (a) the prospective Early Dengue (EDEN) Infection and
Outcomes study [20,30] that studied 455 individuals with
undifferentiated fever at presentation and (b) the Adult Retro-
spective Dengue Study at Tan Tock Seng Hospital (ARDENT)
that compiled characteristics of dengue patients who presented
there from 2004 to 2008. That hospital treated circa 40% of all
reported dengue cases over this time period.
Epidemic and economic parameters were obtained from EDEN
and ARDENT, the literature, official sources and consultation
with the National Environment Agency that is responsible for
vector control (Tables 1 and 2).
Degree of underreporting
Underreporting was corrected using expansion factors [21] (EF)
to scale reported cases. As more severe cases, such as those
hospitalized, are much more likely to be reported than mild cases
treated in ambulatory care, we distinguished between two
expansion factors: EFh for hospitalized cases (EFh was conserva-
tively estimated from the lower bound estimates from the literature
[22,31]); and EFai for ambulatory cases in age group i. To estimate
EFai for different age groups, we employed the results from a
serological study in 2004 among 18 to 74 year olds as part of the
National Health Survey [32]. The sampling was considered
representative of the population because participants were
recruited from different sentinel sites across the country, and
selected by a combination of stratified and systematic sampling.
The study results were used to infer total prevalence of dengue
infection in each age group. The total dengue symptomatic
prevalence in each age group was then estimated by multiplying
the total number of serologically identified dengue cases by
symptomatic rates. Given the uncertainty regarding symptomatic
rates, we considered two main scenarios: (i) an age-dependent
symptomatic rate [33]; and (ii) a constant range of symptomatic
rates [34,35]. Seroconversion for children during that period was
not available and we therefore assumed that the expansion factor
for the young adults applied also for children.
Direct costs
We considered both medical and non-medical direct costs.
Direct medical costs were calculated for hospitalized and
ambulatory cases. Daily hospitalization costs were obtained from
the distribution of hospital bills per dengue patient provided by
public Singaporean hospitals in 2010 for unsubsidized wards,
divided by the median length of stay [36]. The median and 90th
percentile daily costs per patient were used to construct a normal
distribution (Table 2). The costs of ambulatory cases were
obtained by multiplying the average number of visits per case by
the unit costs of each visit (Tables 1 and 2). The costs included
consultation fees, tests performed, and treatment costs (Table 2).
Non-medical direct costs include individual and family transport
costs (Table 2), and control costs which were obtained from the
National Environment Agency. All costs were expressed in 2010
US dollars.
Indirect costs
Indirect costs were expressed per unspecified day and included
reduction of work productivity, reduction of household services,
loss of schooling, and increased need for caregivers. To estimate
Author Summary
Dengue illness is a tropical disease transmitted by
mosquitoes that threatens more than one third of the
worldwide population. Dengue has important economic
consequences because of the burden to hospitals, work
absenteeism and risk of death of symptomatic cases.
Governments attempt to reduce the disease burden using
costly mosquito control strategies such as habitat reduc-
tion and spraying insecticide. Despite such efforts, the
number of cases remains high. Dengue vaccines are
expected to be available in the near future and there is
an urgent need to evaluate their cost-effectiveness, i.e.
whether their cost will be justified by the reduction in
disease burden they bring. For such an evaluation, we
estimated the economic impacts of dengue in Singapore
and the expected vaccine costs for different prices. In this
way we estimated price thresholds for which vaccination is
not cost-effective. This research provides useful estimates
that will contribute to informed decisions regarding the
adoption of dengue vaccination programs.
Dengue Vaccine Cost-Effectiveness
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work productivity loss, the World Health Organization (WHO)
proposes two main methods, both of which we used: the human
capital and the friction cost method [37]. The human capital
method values lost time or premature death using the individual’s
gross earnings, derived from the gross domestic product per capita.
The more conservative (lower cost) friction cost method acknowl-
edges that job absenteeism or death lead to productivity losses that
can be temporarily offset by colleagues or by hiring new labour
[38], so that the loss of productivity occurs only during a friction
time period (assumed to be in our case 30 days for fatalities and to
last as long as symptoms in non-fatal cases) and productivity losses
are offset according to the elasticity of annual labour time versus
labour productivity (Table 1). Friction costs were then calculated
by multiplying the length of the friction period with the expected
average gross earnings in the period and the elasticity of annual
labour time versus labour productivity. The costs of school days
lost were estimated from the expenditures on schools in Singapore
per student per day [10,39].
We also estimated the impact on household services, which are
not paid for but represent important economic activity (e.g.
cleaning, cooking, caring for children and the elderly) (Table 2)
[40]. Losses of household services affect not only the working
population but also the young and the elderly [40].
We assumed that symptomatic children with two working parents
but without household help caused further job absenteeism. For the
elderly, only those outpatients living alone were assumed to require
a caregiver (Table 2). For cases where care was given by a member
of the family not actively working, the care givers incurred a loss of
household services.
DALYs estimation
Different disability weights for DF and DHF have been used in
previous studies. For comparison, we employ three sets of
disability weights: the first, based on recent literature estimates,
reflects that all symptomatic cases are incapable of carrying out
normal daily activities during illness [9,16,41,42]; the second based
on WHO disability weights [43]; and the third has weights
obtained in a empirical study that measured daily the losses in
quality of life through the course of the infection using the visual
thermometer-like scale technique [44,45] (Table 1). A disability
weight of 1 was used for premature death. DALYs lost by each
case were calculated using [41]:
{
DCe{ba
bzrð Þ2 e
{ bzrð ÞL 1z bzrð Þ Lzað Þð Þ{ 1z bzrð Það Þ
h i
where D is the disability weight; r is the social discount rate; a is the
age of the individual at the onset of symptoms; L is the duration of
the disability or the years of life lost due to premature death
Table 1. Epidemic and DALY parameters.
Parameter Value Source
Age parameter of logistic model relating age with probability of clinical dengue 0.164{ [33]
Proportion of symptomatic cases using non age-structure rates 0.24–0.53 [34,35]
EFa1 15 to 24 years old using age-dependent; constant symptomatic rates 3.8; 1.7–3.6 Estimated from [32,33,34,35]
EFa2 25 to 34 years old using age-dependent; constant symptomatic rates 13.1; 3.8–8.2 Estimated from [32,33,34,35]
EFa3 35 to 44 years old using age-dependent; constant symptomatic rates 24.3; 6.1–13.4 Estimated from [32,33,34,35]
EFa1 45 to 54 years old using age-dependent; constant symptomatic rates 45.3; 11.1–24.2 Estimated from [32,33,34,35]
EFa1.55 years old using age-dependent; constant symptomatic rates 50; 12.2–26.5 Estimated from [32,33,34,35]
Expansion factors for hospitalised cases, EFh 1.4–3.4 [22,31]
Number of ambulatory visits per episode 4.33 ARDENT project
Average length of hospitalization (days) 4.6–4.8 [20,59], ARDENT project
Number of fatalities from 2000 to 2009. 98¥ [29]
Disability weight for symptomatic cases of DF from WHO and the literature, D 0.211; 0.81 [9,43]
Disability weight for symptomatic cases of DHF from WHO and the literature, D 0.5; 0.85 [42,43]
Mean disability weight for symptomatic ambulatory and hospitalized children cases, D 0.37; 0.521 [44]
Mean disability weight for symptomatic ambulatory and hospitalized adult cases, D 0.42; 0.531 [44]
Social discount rate for DALYs calculations, r 0.03 [41,60]
Age-weighting correction constant, C 0.16243 [41]
Parameter of the age-weighting function, b 0.04" [41]
Duration of disability in reported cases (days) 10.4 [20,59], ARDENT project
Duration of disability in unreported cases (days) 4 [16]
Duration of disability in DHF cases (days) 14 [11,61]
Proportion of cases reported that are hospitalized 0.565 [20,59], ARDENT project
Proportion of hospitalized cases that are DHF 0.358 ARDENT project
{The intercept of the linear model was estimated to be 22.94 [33].
1Estimated from Figure 1 in [44] for 10 days of symptoms.
¥Deaths per year: 2000: 2; 2001: 6; 2002: 6 ; 2003: 6 ; 2004: 8 ; 2005: 27 ; 2006: 10; 2007: 24 ; 2008: 2 ; 2009: 8. No expansion factors were applied to the number of deaths.
"The age weighting function represents the value of life at different ages. It reflects the different social roles of individuals at different ages, i.e. young and elderly
require care giving [41].
doi:10.1371/journal.pntd.0001426.t001
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expressed in years; C is the age-weighting correction constant; and
b is the parameter from the age-weighting function. The age-
weighting function represents the value of life at different ages [41]
(Table 1).
Vaccine cost-effectiveness
Because the eventual price of the vaccine is very uncertain,
instead of assuming one single price we estimated the threshold
price above which vaccination programs of different characteris-
tics would not be cost-effective [25]. We compared the cost-
effectiveness of the vaccines with the current vector control
program ($4,740 per DALY averted [46] ) and the criterion for
cost-effective health interventions of WHO (cost per DALY
averted below 3 times the gross national income per capita [47]).
We considered a scenario of mass vaccination allocated at
random to a proportion of the population. The vaccination
program could require two or three doses and could confer
lifetime or only ten years immunity, leading to a total of four
combinations of vaccine characteristics.
Vaccine cost-effectiveness was evaluated for a time period of 75
years equivalent to the country’s average life expectancy. Average
annual estimates of DALYs and economic impacts were estimated
per capita for each age group from 2000 to 2009 and used to
project economic impacts and DALYs using the population levels
and age structure in Singapore as predicted in the United Nations
World Population Prospects 2010 Revision from 2012 to 2086
[48]. By 2086, Singapore is expected to increase its population
from 5.3 million of 6.5 million and to increase the proportion of
habitants above 65 years old from 11% to 40% [48].
To estimate the critical vaccination coverage (fc) we considered
the largest dengue epidemic in Singapore during the last 10 years,
which occurred in 2005 [49] . It has been estimated that the basic
reproductive number (R0, where an outbreak with an R0 below 1
dies out naturally [50]) fell in the range 1.89–2.23 [49]. The
vaccine coverage fc to bring the basic reproduction number R0
below 1 with a vaccine of efficacy c is:
fc~
1
c
1{
1
R0
 
we assumed that vaccine programs attaining herd protection
greater than or equal to fc would prevent epidemics of dengue in
Singapore (ignoring localised non-sustainable outbreaks following
importation).
Results
Underreporting
The serological study in 2004 tested for IgG and IgM antibodies
among 4152 individuals. Of the study population, 59.0% and
Table 2. Economic parameters (2010 US $).
Parameter Value Source
Hospital costs per hospitalized case per day ($) Normal(431,597)* [36]
Transport costs to seek medical care and household members visiting patients ($) 3.7{ [62]
Average costs per ambulatory visit ($) 62.11 ARDENT project
Average productivity loss per absent day of work in individuals from 18 to 64 years ($) 163{ [63]
Average household services losses per day ($) 35¢ [40]
Elasticity of annual labour time versus labour productivity Uniform(0.6,0.9) [38]
Proportion of children that require a parent to be absent from work for care giving 0.43¥ [64]
Proportion of elderly needing to hire a care giver 0.073" [65]
Cost of providing primary education per student per day 21I [39]
Cost of providing secondary education per student per day 29.3I [39]
Discount rate for premature deaths productivity lost 0.03 [60]
Vaccine effectiveness (%) 80{{ [53]
Vaccine overhead, labour, syringes, distribution and storage costs per dose ($) 7e [52]
Annual expenditure on dengue control ($ million) 50 NEA
*Estimated using the bill sizes per dengue patient and day. The distribution was truncated to only positive values.
{Average daily ridership and average round trip distance used to calculate weighted average transportation cost. It includes Mass Rapid Transport and Light Rapid
Transport systems, bus, and taxi. An average of two family visits per day per inpatient are assumed. Transport in Singapore is not subsidized [66].
1Includes the costs and proportion of patients tested using dengue PCR ($111.5) or serology tests ($25.9) in the first consultation , medical officer consultation fees
($30.9 for first consultation and $24.3 subsequent consultations), cost of full blood count in all consultations ($16.4), urea ($6.7), protein ($7.1), ALT ($7.1) and AST ($7.1)
tests and cost of symptoms relief medicaments ($6.6 including paracetamol for fever, metocloperamide for vomiting, peritoh for itch and famotidine for gastric
irritation).
{Obtained by dividing the GDP per capita by the working days per year. The productivity loss by an undetermined day of work is obtained by dividing the GDP per
capita by 365 days.
¢Due to lack of data on allocation of hours to household activities in Singapore, we employ US cost data expressed in US 2010 $. In the model we distinguish the
household service losses per day in the age groups: 15–17 ($15), 18–29 ($26), 30–64 ($40), 65–74 ($45) and .75 ($38).
¥Families in this situation are assumed to be families with all working parents, without maid and without unemployed or retired family members available to give care
to the children. The proportion of children belonging to families where nobody cooks at home is used as a surrogate for these families [64] . For the rest of the families,
the care giver is imputed a cost corresponding to the household services that cannot be carried out during the time of care giving.
"The estimate corresponds to the number of persons .65 years old living alone. A social worker with a salary of $13/hour is assumed to be hired as care giver 8 hours a
day. For the rest of elderly the care givers are imputed a cost equal to their household services.
IAverage government expenditure divided by total number of primary or secondary students and total school days.
{{Low effectiveness as compared to previous studies assuming 95% [53] to reflect the difficulty of obtaining a vaccine for the four serotypes.
eCorresponds to Panama in [52] .
doi:10.1371/journal.pntd.0001426.t002
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2.6% tested positive for dengue IgG and IgM that are indicative
of past and recent infection (within the last three months),
respectively. The rate of recent infection ranged from 1.2% in
individuals from 15 to 24 years old to 3.2% in individuals from 45
to 54 years old [32]. We assume that the number recently
infected in the time period of the study is representative of
the proportion infected in the country for that time period. From
the 2004 population age structure, we estimated that 71,134
individuals were recently infected – encompassing symptomatic
and asymptomatic cases – nationally in the period of the study.
The number of reported cases during the same time period was
3104. To obtain the number of symptomatic infected individuals,
we multiplied the estimated number of individuals recently
infected with symptomatic rates. Due to uncertainty in the
asymptomatic rates in each age group, we considered two
scenarios to obtain expansion factors. In the first scenario, we
multiplied the expected number of infected individuals with age-
dependent symptomatic rates obtained from a logistic model [33].
In a second scenario, we multiplied by a range of constant
symptomatic rates for all ages of 24% to 53% [34,35]. We
obtained two sets of expected number of infected symptomatic
cases per age group, and compared this with the cases reported
per age group. In the first scenario, the expansion factors ranged
from 3.8 in the youngest group (0–24 years) to 50 in the oldest
group (.55 years) (Table 1). The second scenario yielded
expansion factors ranging from 1.7–3.6 for 0–24 years to 12.2–
26.5 for .55 years. The proportion of underreporting increased
with age in both scenarios.
Economic and disease burden
The mean economic impact was mostly driven by the number of
cases per year, resulting in high variability (Figure 1). For instance,
combining the human capital method and non-age-dependent
symptomatic rate scenarios during the 2005 epidemic led to costs of
US $160 million, more than double the cost in 2000 ($64 million,
Figure 1).
Using the human capital method and non-age-dependent
symptomatic rates, the distribution of costs from 2000 to 2009
excluding control costs had a mean of $415 million ($41.5 million
per year) with 5th and 95th percentiles of $299 and 569 million
(Table 3). Using the friction cost method, the mean was $351 million
with 5th and 95th percentiles of $236 and 504 million. Total control
costs were $500 million. Hence the total economic costs from 2000
to 2009 were $0.91 billion using the human capital method or $0.85
billion using the friction cost method. Using age-dependent
symptomatic rates, the total cost estimates increased to $1.06 billion
by the friction cost method and $1.15 billion by the human capital
method (Table 3). The costs due to deaths decreased considerably
under the friction cost method (Table 3). Whereas age-dependent
symptomatic rates led to a higher proportion of costs due to
ambulatory cases, hospitalized cases represented the largest share of
costs when constant symptomatic rates were used (Table 3). The
relative percentage of costs due to hospitalized cases and deaths
decreases with respect to ambulatory costs when considering age-
dependent symptomatic rates (Table 3, columns 5th and 6th). The
reason is that, whereas using age-dependent symptomatic rates
leads to higher expansion factors estimated for ambulatory cases
Figure 1. Economic impacts of dengue in Singapore. Mean total economic impacts, costs from hospitalized cases, costs from ambulatory cases
and from fatalities due to dengue in Singapore from 2000 to 2009 using the human capital method and constant symptomatic rates.
doi:10.1371/journal.pntd.0001426.g001
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than using constant symptomatic rates, the number of fatalities and
the expansion factors for hospitalized cases does not vary.
Using empirically derived disability weights [44], average
DALYs per 100,000 population were 8.7 (5th and 95th percentiles
of 8 and 10) when using constant symptomatic rates and 14 (5th
and 95th percentiles of 13 and 16) when using age-dependent
symptomatic rates (Table 4). DF made up 24–32% of the disease
burden, non-fatal DHF 33–57%, and dengue related deaths 9–
43% (Table 4). For comparison with previous studies we repeated
the analysis with disability scores from WHO [51] (Table 4, 8–8.9
DALYs per 100,000 population) and with literature disability
scores (16–27 DALYs per 100,000 population).
Vaccine cost-effectiveness
We conservatively evaluated the cost-effectiveness of vaccines
using constant symptomatic rates and empirically derived
disability weights. Assuming the worst dengue epidemic of
R0 = 2.5 and a vaccine of efficacy c= 0.8 (to reflect the difficulty
to obtain a vaccine effective to the four serotypes), the critical
herd protection needed against the four serotypes to prevent
dengue epidemics (fc) would be 75%. The actual herd
protection in Singapore is uncertain. Under the conservative
assumption of a completely dengue-naı¨ve population, a general
vaccination program covering 75% of the population would be
expected to prevent dengue epidemics within one year of
completion.
Conservatively assuming that vector control costs remain
constant, we evaluated the vaccine programs’ cost-effectiveness
with increasing vaccine prices (Figure 2). The threshold price
beyond which vaccines would not be cost-effective increased when
fewer doses were needed and longer immunity was conferred. For
low prices, vaccines presented net savings per DALY averted
(avoided costs were greater than vaccination costs) and were very
cost-effective. The price per dose threshold beyond which vaccines
stopped being more cost-effective than the current vector control
program ranged from $53 for mass vaccination requiring 3 doses
and only conferring 10 years of immunity to $287 for vaccination
requiring 2 doses and conferring lifetime immunity (Figure 2 A).
The thresholds for vaccine program cost-effectiveness in Singapore
ranged from $95 and $491 per dose respectively (Figure 2 B). For
sensitivity analysis purposes, assuming instead that the population
size and age structure remained constant in the future in
Singapore, the thresholds for these vaccine programs to not be
cost-effective in Singapore were lower ($70 and $212 respectively)
due to their lower potential avoidance of the economic burden of
dengue.
Sensitivity analysis
We evaluated the sensitivity of the mean estimated disease
burden, total costs and the benefit-cost ratio of the vaccination
programs to the model parameters considering both ten-year and
lifelong immunity. We performed univariate sensitivity analysis
where all parameters were increased by 30% to evaluate their
relative importance. The analysis showed that disease burden
estimates were sensitive to the parameters: length of symptoms of
DHF cases (increase of 16%), disability weight for DF cases
(increase of 19%) and the proportion of DHF cases (increase of
10%). The total cost estimations were sensitive to the expansion
factor used for hospitalized cases (increase of 14%), hospitalization
costs per day (increase of 11%) and length of hospital stay (increase
of 10%).
The benefit-cost ratios of a mass vaccination program
conferring lifelong immunity decreased when increasing the
discount rate used (18%), costs of overhead, vaccine storage and
distribution (22%), the number of doses needed (28%) and the
required herd protection to drive R0 below 1 (27%). The same
direction in sensitivity was obtained for vaccine programs
conferring ten-year immunity. However, the magnitude of the
effects increased by 5%, on average, compared to the estimates for
lifelong immunity.
Table 3. Economic impacts of dengue in Singapore.
Method
Symptomatic
rate
TC ($ billion)
without control
% ambulatory
costs
% hospitalized
costs
% death
costs
% costs lost
productivity
TC ($ billion)
with control
Human capital Constant 0.41 (0.30; 0.57) 43 47 10 24 0.91
Age-dependent 0.65 (0.53; 0.80) 62 32 6 29 1.15
Friction cost Constant 0.35 (0.24; 0.50) 47 53 0.2 21 0.85
Age-dependent 0.56 (0.45; 0.72) 67 34 0.1 25 1.06
doi:10.1371/journal.pntd.0001426.t003
Table 4. Disease burden of dengue in Singapore.
Disability weights Symptomatic rate
Total disease burden
(DALYs/100000) % DF DALYs % DHF DALYs % death DALYs
From literature [9,16] Constant 16.0 (13.2; 18.0) 31 54 16
Age-dependent 27.4 (23.3; 31.3) 34 57 9
From WHO [43] Constant 5.8 (5.2, 6.5) 24 33 43
Age-dependent 8.9 (7.9; 9.9) 26 49 25
Empirically derived [44] Constant 8.7 (7.7; 9.9) 27 45 28
Age-dependent 14.4 (12.6; 16.4) 32 50 18
doi:10.1371/journal.pntd.0001426.t004
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Discussion
The burden of disease due to dengue infections is high across at-
risk areas of the world. Even with good vector control, as
Singapore has, permanent reduction of dengue epidemics has
proven to be impossible, and vaccines may be the only hope for
sustained control. Our analysis demonstrates that dengue imposes
a significant disease and economic burden in Singapore. The cost-
effectiveness of vaccines will depend on their price and
characteristics.
To be able to estimate how cost-effective the vaccines will be, a
baseline price can be used. Considering a price per dose of $5
(based on the projected price of a dose of pneumococcal vaccine)
from a cost-effectiveness study for dengue vaccines in Panama, a
middle income country [52], all the vaccination programs
considered would be very cost-effective and would provide net
savings per DALY averted, which is in stark contrast with current
costs of $4,740 per DALY averted by the vector control program
[46] and with a vaccine cost-effectiveness evaluation of $50 per
DALY averted with prices of routine vaccines in resource-limited
settings ($0.50 per dose in the public sector [53]). However, the
price of recently developed vaccines in Singapore is much higher
(e.g. US $124 per dose of pneumoccal vaccine for 3 required doses)
[54]. If we use the considerably higher price of US $124 per dose
as the baseline price, for mass vaccination to be cost-effective, it
would have to guarantee lifetime immunity. At this high price the
vaccination programs involving 3 doses and conferring only 10
years of immunity would not be more cost-effective than the vector
control program (Figure 2); however, the other programs involving
lifetime immunity or only two doses would be more cost-effective
than vector control. The comparison with the cost-effectiveness of
the vector control program, however, is only illustrative: a
vaccination program might still be preferred as long as the cost
per DALY averted is below three times the gross national income
per capita, since deaths due to dengue will be avoided and they
would have been unavoidable under the current vector control
program. This reflects the importance of the substantial incre-
mental costs of the vector control program to attain lower than
current disease burdens. Using three times per capita gross
national income as the cost-effectiveness threshold [47], the price
threshold of the vaccines is very high. For instance, a vaccine
involving three doses and conferring only ten years of immunity
would be cost-effective up to a price threshold of $95 per dose
(Figure 2).
Our results on total costs were sensitive to hospitalization costs.
This reflects the high hospitalization costs of Singapore relative to
other South East Asian countries, e.g. Thailand, where non-
hospitalized cases represented a substantial proportion of the
overall burden of the disease [13]. Ambulatory cases, however,
also represent a large share of the total costs due to dengue in
Singapore (Table 3).
The disease burden of dengue in Singapore (9–14 per 100,000
population) using empirically derived disability weights is compa-
rable to diseases like hepatitis B or syphilis (10 and 9 DALYs per
100,000 respectively). Using disability weights from the literature
[9,16] dengue is comparable to meningitis and multiple sclerosis
(22 and 19 DALYs per 100,000, respectively, versus our estimated
16–27) [43]. It is, though, lower than other tropical and
subtropical countries (e.g. 66 in Puerto Rico [9], 42.7 in Thailand
[16] and 26.5 DALYs per 100000 in Brazil [11], where the
estimates were obtained using the same disability weights from the
literature). Different estimates were also obtained when using
WHO disability weights (Table 4), and consensus would be
necessary for results to be comparable across studies.
The lower disease burden per capita in Singapore compared to
other studies may be due to its intensive vector control program,
which represents the greatest component of dengue costs (42–
59%). This may indicate that vector control in Singapore is
attaining its maximum expected effectiveness. Given the high
endemicity levels of dengue in Southeast Asia and the constant
movement of persons and commodities between the countries in
the region, increasing the efforts in vector control would likely
meet with diminishing returns in dengue incidence. Hence, an
effective dengue vaccine remains an attractive option for long-
term and sustainable dengue prevention. We found that for
reasonably low prices, vaccines are a promising and cost-effective
option to reduce cases further. However, the extent to which
vaccination might reduce necessary vector control expenditures is
unknown, as vector control would still be necessary to prevent
outbreaks of other mosquito-borne diseases e.g. chikungunya,
which reached Singapore in 2008 [55]. On the other hand, if
vector control activities were reduced as a result of the vaccination
program, the cost-effectiveness of the vaccines would be higher.
We preferred, however, to adopt a conservative approach by
considering no reductions in the costs of the vector control as a
result of the vaccination program. At the same time, improve-
ments in vector control technology such as application of genetic
modification techniques to the Sterile Insect Technique [56] or the
Figure 2. Cost-effectiveness of dengue vaccines. Cost per DALY averted for mass vaccination programs requiring 2 and 3 doses. A: the vaccine
confers lifetime immunity; B: the vaccine confers 10 years immunity. 3*GNI indicates the trice of the gross national income per capita. A comparison
between the costs per DALY averted of the different vaccination programs with the current cost per DALY averted of the vector control program
(‘‘vector control program’’) and the cost-effectiveness threshold (3NGNI) is made. When the costs per DALY averted are higher than the costs per DALY
averted of the vector control program, the vector control program is comparatively more cost-effective. If the costs per DALY averted are higher than
3NGNI, the vaccination program is not cost-effective for Singapore.
doi:10.1371/journal.pntd.0001426.g002
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introduction of the bacterium Wolbachia in mosquito populations
[57] might be attractive alternatives or complements to vaccina-
tion, especially when the timeline for availability of vaccines, their
eventual efficacy and length of protection are unknown.
The main limitations of the study reside in the presence of
uncertainty regarding key parameters. For instance, the vaccine
might be less effective than assumed and be associated with high
post-implementation costs. These factors would reduce the price
threshold for which the vaccine would be cost-effective, but given
the large margin of error for the vaccine to be cost-effective and
the conservative approach adopted, we are confident that for
reasonably low prices, the vaccine will be cost-effective in
Singapore.
We have not evaluated the cost-effectiveness of purely pediatric
vaccines since their implementation would involve only partial
protection of the population, and to estimate their cost-
effectiveness would require an epidemic model capturing the
dynamics of dengue in Singapore and able to relate partial
population immunity with disease prevalence would be necessary.
The construction of such an epidemic model would be a complex
undertaking given the high uncertainty regarding the mechanisms
that drive dengue dynamics in Singapore, and so this was left for
future research. We postulate however that pediatric vaccines are
likely to be also cost-effective [53] although it might take 10 to 20
years to notice their effect on disease burden reductions.
The estimation of the economic and disease burdens also
presented limitations. We were unable to estimate the intangible
costs due to the extra burden of dengue epidemics to the health
system; we also could not find a significant relationship between
dengue cases and volume of tourism or other economic sectors in
Singapore. The exclusion of these economic impacts makes our
estimate of the economic burden conservative. Uncertainty was
also present in the estimation of underreporting, or expansion
factors. We were unable to estimate expansion factors for
hospitalized cases and had to rely on existing literature. To gauge
the lower bound of our estimates, assuming that all hospitalized
cases are reported (EFh = 1), the total costs would be reduced by
18%. For ambulatory cases, the availability of national serological
surveys compared with nationally reported cases gives strong
confidence in our estimates. The symptomatic rate estimates
however, presented high variability per age group and were scarce
in the literature, leading to rather different disease burden
estimates. To account for this uncertainty, two scenarios were
considered, with broadly similar findings. Nonetheless, further
research on symptomatic rates per age group would be beneficial
to derive future estimates. Using age-dependent symptomatic
rates, our estimates of expansion factors for age groups below 44
years old (3.8, 13.1 and 24.3) were approximately equivalent to
those in other studies, e.g. Brazil (2.1–10), Colombia (4.5–18) or
Puerto Rico (10–27) [11] but were higher in older age groups (45.3
and 50). Using constant asymptomatic rates, the expansion factors
matched these estimates from the literature. Comparison between
studies is difficult because age-dependent expansion factors for
multiple age-groups are rarely calculated. One exception is
Meltzer et al. [9], who estimated expansion factors of 10 for 0–
15 years old and 27 for cases above 15 years old, which is in
agreement with our results regarding increasing underreporting
with age. The reason for underreporting increasing with age might
be due to parental influence for the young [9] and/or atypical
disease manifestations of the elderly [58].
In summary, we demonstrated the high economic and disease
burden of dengue in Singapore and our results strongly support
the implementation of vaccination programs if reasonably low
prices are adopted. Vaccines will assist in Singapore as a mean to
curb the economic and health burden of dengue illness.
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